Expert Interview
Discussing Immunic's Phase 2 results for vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS).
Ticker(s): IMUXInstitution: Holy Name Medical Center
Board-certified neurologist and Medical Director of the MS Center at Holy Name Medical Center since 1993
Treats ~1500 patients with multiple sclerosis per year, with extensive expertise in disease modification, symptom management, and quality of life interventions
Research focus includes clinical trials in MS, psychosocial interventions, and patient-centered care; author and editor of several books including MS for the Non-Neurologist
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Sep 19, 2025
- Call Time
- 09:00 AM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
